Yannick Galipeau

862 total citations
26 papers, 340 citations indexed

About

Yannick Galipeau is a scholar working on Infectious Diseases, Neurology and Epidemiology. According to data from OpenAlex, Yannick Galipeau has authored 26 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Infectious Diseases, 5 papers in Neurology and 4 papers in Epidemiology. Recurrent topics in Yannick Galipeau's work include SARS-CoV-2 and COVID-19 Research (23 papers), COVID-19 Clinical Research Studies (16 papers) and SARS-CoV-2 detection and testing (5 papers). Yannick Galipeau is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (23 papers), COVID-19 Clinical Research Studies (16 papers) and SARS-CoV-2 detection and testing (5 papers). Yannick Galipeau collaborates with scholars based in Canada, United States and Morocco. Yannick Galipeau's co-authors include Marc‐André Langlois, Matthew Greig, Chaojie Liu, Curtis Cooper, Yves Durocher, Michaeline McGuinty, Julian Little, Éric Boilard, Loubna Khalki and Alain Brisson and has published in prestigious journals such as Nature Communications, PLoS ONE and The FASEB Journal.

In The Last Decade

Yannick Galipeau

23 papers receiving 337 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yannick Galipeau Canada 8 270 51 41 40 38 26 340
Disha Bhavsar United States 5 349 1.3× 46 0.9× 43 1.0× 49 1.2× 39 1.0× 13 401
Stéphane Marot France 10 314 1.2× 49 1.0× 34 0.8× 33 0.8× 27 0.7× 32 378
Sara Caldrer Italy 8 168 0.6× 60 1.2× 27 0.7× 35 0.9× 47 1.2× 19 355
Constant Gillot Belgium 11 426 1.6× 66 1.3× 86 2.1× 46 1.1× 62 1.6× 23 477
Diane Yang United States 4 430 1.6× 68 1.3× 41 1.0× 21 0.5× 43 1.1× 6 465
Patrizia Casprini Italy 8 286 1.1× 23 0.5× 64 1.6× 27 0.7× 18 0.5× 15 353
Samuel Rigby United Kingdom 5 514 1.9× 55 1.1× 32 0.8× 33 0.8× 61 1.6× 9 587
Catherine Huntley United Kingdom 5 514 1.9× 71 1.4× 33 0.8× 30 0.8× 64 1.7× 11 620
Christine Eucher Belgium 11 474 1.8× 53 1.0× 78 1.9× 24 0.6× 38 1.0× 14 494
Sandrine Van Eeckhoudt Belgium 8 380 1.4× 41 0.8× 50 1.2× 20 0.5× 36 0.9× 11 405

Countries citing papers authored by Yannick Galipeau

Since Specialization
Citations

This map shows the geographic impact of Yannick Galipeau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yannick Galipeau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yannick Galipeau more than expected).

Fields of papers citing papers by Yannick Galipeau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yannick Galipeau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yannick Galipeau. The network helps show where Yannick Galipeau may publish in the future.

Co-authorship network of co-authors of Yannick Galipeau

This figure shows the co-authorship network connecting the top 25 collaborators of Yannick Galipeau. A scholar is included among the top collaborators of Yannick Galipeau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yannick Galipeau. Yannick Galipeau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Galipeau, Yannick, Corey Arnold, Martin Pelchat, et al.. (2025). Autoantibodies targeting angiotensin‐converting enzyme 2 are prevalent and not induced by SARSCoV ‐2 infection. The FASEB Journal. 39(4). e70390–e70390.
2.
Galipeau, Yannick, Curtis Cooper, & Marc‐André Langlois. (2025). Autoantibodies in COVID-19: implications for disease severity and clinical outcomes. Frontiers in Immunology. 15. 1509289–1509289. 4 indexed citations
5.
Siragam, Vinayakumar, et al.. (2024). Seasonal human coronaviruses OC43, 229E, and NL63 induce cell surface modulation of entry receptors and display host cell-specific viral replication kinetics. Microbiology Spectrum. 12(7). e0422023–e0422023. 3 indexed citations
6.
Galipeau, Yannick, et al.. (2024). Reduced seasonal coronavirus incidence in high‐risk population groups during the COVID‐19 pandemic. Immunity Inflammation and Disease. 12(7). e1342–e1342. 2 indexed citations
7.
Almeida, N., Ian Schiller, Danbing Ke, et al.. (2024). The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study. Frontiers in Immunology. 15. 1330549–1330549. 3 indexed citations
8.
Čuperlović‐Culf, Miroslava, Steffany A. L. Bennett, Yannick Galipeau, et al.. (2024). Multivariate analyses and machine learning link sex and age with antibody responses to SARS-CoV-2 and vaccination. iScience. 27(8). 110484–110484.
9.
Galipeau, Yannick, Ronald A. Booth, Curtis Cooper, et al.. (2024). Clinical and serological predictors of post COVID-19 condition–findings from a Canadian prospective cohort study. Frontiers in Public Health. 12. 1276391–1276391. 2 indexed citations
10.
Galipeau, Yannick, Danijela Konforte, Mohamed Abou El Hassan, et al.. (2023). Cross-sectional Characterization of SARS-CoV-2 Antibody Levels and Decay Rates Following Infection of Unvaccinated Elderly Individuals. Open Forum Infectious Diseases. 10(8). ofad384–ofad384. 2 indexed citations
11.
Galipeau, Yannick, et al.. (2023). Continuous false positive results by SARS-CoV-2 rapid antigen testing: a case report. Frontiers in Public Health. 11. 1240308–1240308. 2 indexed citations
13.
Galipeau, Yannick, et al.. (2022). Seasonal respiratory virus circulation was diminished during the COVID‐19 pandemic. Influenza and Other Respiratory Viruses. 17(1). e13065–e13065. 17 indexed citations
14.
Puhm, Florian, Isabelle Allaeys, Isabelle Dubuc, et al.. (2022). Platelet activation by SARS-CoV-2 implicates the release of active tissue factor by infected cells. Blood Advances. 6(12). 3593–3605. 40 indexed citations
15.
Galipeau, Yannick, Tyler M. Renner, Lise Deschatelets, et al.. (2022). Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice. Vaccines. 11(1). 30–30. 6 indexed citations
16.
Erwin, Erica, Malia S. Q. Murphy, Alysha L. J. Dingwall‐Harvey, et al.. (2022). Prevalence of SARS-CoV-2 infection among obstetric patients in Ottawa, Canada: a descriptive study. CMAJ Open. 10(3). E643–E651. 1 indexed citations
17.
Kim, Sun Jin, Zhong Yao, Debra M. Eckert, et al.. (2022). Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies. Nature Communications. 13(1). 3716–3716. 17 indexed citations
18.
Erwin, Erica, Malia S. Q. Murphy, Alysha L. J. Dingwall‐Harvey, et al.. (2022). Universal SARS-CoV-2 Testing Among Obstetrical Patients (UNIVERSE-OB) in Ottawa, Canada. Journal of Obstetrics and Gynaecology Canada. 44(5). 600–600. 1 indexed citations
20.
Galipeau, Yannick, et al.. (2020). Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Frontiers in Immunology. 11. 610688–610688. 160 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026